Home › Trial NCT06890182
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
- Trial IDNCT06890182
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorTianjin Medical University Cancer Institute and Hospital
- Enrollment31
- Start date2025-03
- ConditionsNon-small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.